Qiagen's HC2 More Effective Than Pap Test In Preventing Cancer - Study
This article was originally published in The Gray Sheet
Executive Summary
Qiagen/Digene's Hybrid Capture 2 human papillomavirus (HPV) DNA test is more effective than Pap testing alone in preventing cervical cancer, according to the results of a large-scale study published online Jan. 19 in The Lancet Oncology
You may also be interested in...
HPV Testing Evidence Examined In Cervical Cancer Screening Guidelines
The U.S. Preventive Services Task Force finds the evidence inconclusive for employing human papillomavirus testing as part of cervical cancer screening for women over 30, and it explicitly recommends against HPV testing in younger women.
HPV Testing Evidence Examined In Cervical Cancer Screening Guidelines
The U.S. Preventive Services Task Force finds the evidence inconclusive for employing human papillomavirus testing as part of cervical cancer screening for women over 30, and it explicitly recommends against HPV testing in younger women.
Research In Brief
HPV screening: Primary human papilloma virus DNA screening with Qiagen/Digene's Hybrid Capture 2 followed by cytology triage is more sensitive in detecting cervical lesions than conventional cytology screening, according to a large-scale Finnish study published in the Dec. 2 issue of the Journal of the National Cancer Institute. In women 35 or older, the method also showed greater specificity and decreased colposcopy referrals and follow-up tests. An accompanying editorial by Eduardo L. Franco, McGill University, notes that as more young women who have received the HPV vaccine reach screening age, "the reduced prevalence of abnormalities may adversely affect the performance of cytology if it is left as the sole screening test.